Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an ...

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast ...

Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. ... Read ...

Scientists have developed Spudcell, an advanced synthetic cell capable of adapting to its environment and learning survival skills, marking a breakthrough in synthetic biology.

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure ...

PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...

Sponsored reels, algorithmic recommendations, and predatory marketplace listings routinely flood digital feeds, promising ...